Eli Lilly's legal action targets compounding pharmacies, medical spas, and online sellers that are marketing retatrutide, despite it not being approved for human use. The drug is currently in Phase 3 clinical trials for obesity and type 2 diabetes. Lilly emphasizes that the products being sold on the black market are unverified and pose significant health risks.
The company has reported over 200 referrals to regulatory bodies regarding these illegal sales. Additionally, U.S. Customs and Border Protection has noted a significant increase in the interception of illicit GLP-1 drugs, with seizures more than doubling in July. Lilly's Chief Medical Officer, Dr. David Hyman, and Associate Vice President, Dr.
Max Denning, have both stressed the dangers associated with using these unapproved products. The lawsuits were filed against specific companies, including Aesthetic Envy Cosmetic Centers and Texas Peptides, as part of Lilly's broader strategy to safeguard its product and consumer health